296 related articles for article (PubMed ID: 29299684)
1. Treatment of hepatitis C in special populations.
Suda G; Ogawa K; Morikawa K; Sakamoto N
J Gastroenterol; 2018 May; 53(5):591-605. PubMed ID: 29299684
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the treatment of hepatitis C virus infection for special populations and remaining problems.
Suda G; Sakamoto N
J Gastroenterol Hepatol; 2021 May; 36(5):1152-1158. PubMed ID: 32667068
[TBL] [Abstract][Full Text] [Related]
3. Management of hepatitis C in HIV infected and other immunocompromised individuals.
Seth AK
Trop Gastroenterol; 2006; 27(3):111-7. PubMed ID: 17310553
[TBL] [Abstract][Full Text] [Related]
4. Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in "special populations".
Pol S; Parlati L
Liver Int; 2018 Feb; 38 Suppl 1():28-33. PubMed ID: 29427485
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C direct-acting antiviral agents: changing the paradigm of hepatitis C treatment in HIV-infected patients.
Martel-Laferrière V; Bichoupan K; Dieterich DT
J Clin Gastroenterol; 2014 Feb; 48(2):106-12. PubMed ID: 24172182
[TBL] [Abstract][Full Text] [Related]
6. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.
Falade-Nwulia O; Suarez-Cuervo C; Nelson DR; Fried MW; Segal JB; Sulkowski MS
Ann Intern Med; 2017 May; 166(9):637-648. PubMed ID: 28319996
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
Londoño MC; Riveiro-Barciela M; Ahumada A; Muñoz-Gómez R; Roget M; Devesa-Medina MJ; Serra MÁ; Navascués CA; Baliellas C; Aldamiz-Echevarría T; Gutiérrez ML; Polo-Lorduy B; Carmona I; Benlloch S; Bonet L; García-Samaniego J; Jiménez-Pérez M; Morán-Sánchez S; Castro Á; Delgado M; Gea-Rodríguez F; Martín-Granizo I; Montes ML; Morano L; Castaño MA; de Los Santos I; Laguno M; Losa JE; Montero-Alonso M; Rivero A; de Álvaro C; Manzanares A; Mallolas J; Barril G; González-Parra E; García-Buey L
PLoS One; 2019; 14(9):e0221567. PubMed ID: 31550267
[TBL] [Abstract][Full Text] [Related]
8. Interventions for dialysis patients with hepatitis C virus (HCV) infection.
Prabhu RA; Nair S; Pai G; Reddy NP; Suvarna D
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD007003. PubMed ID: 26287983
[TBL] [Abstract][Full Text] [Related]
9. Regimens for Patients Coinfected with Human Immunodeficiency Virus.
Wyles DL
Clin Liver Dis; 2015 Nov; 19(4):689-706, vi-vii. PubMed ID: 26466656
[TBL] [Abstract][Full Text] [Related]
10. Managing HIV/hepatitis C co-infection in the era of direct acting antivirals.
Rockstroh JK; Bhagani S
BMC Med; 2013 Nov; 11():234. PubMed ID: 24228933
[TBL] [Abstract][Full Text] [Related]
11. HCV-HIV co-infected patients: no longer a 'special' population?
Sulkowski MS
Liver Int; 2016 Jan; 36 Suppl 1():43-6. PubMed ID: 26725896
[TBL] [Abstract][Full Text] [Related]
12. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population.
Sikavi C; Chen PH; Lee AD; Saab EG; Choi G; Saab S
Hepatology; 2018 Mar; 67(3):847-857. PubMed ID: 29108121
[TBL] [Abstract][Full Text] [Related]
14. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study.
Manzardo C; Londoño MC; Castells L; Testillano M; Luis Montero J; Peñafiel J; Subirana M; Moreno A; Aguilera V; Luisa González-Diéguez M; Calvo-Pulido J; Xiol X; Salcedo M; Cuervas-Mons V; Manuel Sousa J; Suarez F; Serrano T; Ignacio Herrero J; Jiménez M; Fernandez JR; Giménez C; Del Campo S; Esteban-Mur JI; Crespo G; Moreno A; de la Rosa G; Rimola A; Miro JM;
Am J Transplant; 2018 Oct; 18(10):2513-2522. PubMed ID: 29963780
[TBL] [Abstract][Full Text] [Related]
15. Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.
Hasson H; Messina E; Merli M; Della Torre L; Morsica G; Bagaglio S; Lazzarin A; Uberti-Foppa C
Int J Infect Dis; 2014 Dec; 29():100-2. PubMed ID: 25449243
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.
Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011644. PubMed ID: 28285495
[TBL] [Abstract][Full Text] [Related]
17. Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.
Campos-Varela I; Moreno A; Morbey A; Guaraldi G; Hasson H; Bhamidimarri KR; Castells L; Grewal P; Baños I; Bellot P; Brainard DM; McHutchison JG; Terrault NA
Aliment Pharmacol Ther; 2016 Jun; 43(12):1319-29. PubMed ID: 27098374
[TBL] [Abstract][Full Text] [Related]
18. Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection.
Flanagan S; Crawford-Jones A; Orkin C
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):691-704. PubMed ID: 25209158
[TBL] [Abstract][Full Text] [Related]
19. [Hepatitis C treatment in special patient groups].
Berenguer M; Jorquera F; Ángel Serra M; Sola R; Castellano G
Gastroenterol Hepatol; 2014 Jul; 37 Suppl 1():23-36. PubMed ID: 25907435
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens.
Chen TY; Jain MK
AIDS Patient Care STDS; 2015 Jun; 29(6):329-37. PubMed ID: 26020726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
